Is vascular biology in preeclampsia better?

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 3, 2009, Pages 375-384

  Myatt, L ^a   Webster, Rose P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular; Nitration oxidative stress; Preeclampsia; Vascular

Indexed keywords

ANGIOGENIC FACTOR; AUTACOID; ENDOGLIN; PEROXYNITRITE; PLACENTAL GROWTH FACTOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TYROSINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

BASEMENT MEMBRANE; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; EDEMA; HUMAN; HYPERTENSION; HYPOXIA; INFLAMMATION; ISCHEMIA; NITRATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA CIRCULATION; PLACENTA DISORDER; PLACENTAL DELIVERY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEINURIA; REVIEW; SYNCYTIOTROPHOBLAST; VASCULAR DISEASE;

BLOOD VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY;

EID: 59849107288     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03259.x     Document Type: Review

References (145)

1. Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, Catalano PM, Morris CD. Pregnancy outcomes in healthy nulliparas who developed hypertension. Obstet Gynecol 2000; 95: 24-8.
2. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003; 22: 203-12.
3. Duvekot JJ, Cheriex EC, Pieters FA, Menheere PP, Peeters LH. Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol 1993; 169: 1382-92.
4. Pritchard JA. Changes in the blood volume during pregnancy and delivery. Anesthesiology 1965; 26: 393-9.
5. Koller O. The clinical significance of hemodilution during pregnancy. Obstet Gynecol Surv 1982; 37: 649-52.
6. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256: H1060-5.
7. Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: Lessons from animal models. Am J Physiol Regul Integr Comp Physiol 2002; 283: R29-45.
8. Browne JC, Veall N. The maternal placental blood flow in normotensive and hypertensive women. J Obstet Gynaecol Br Emp 1953; 60: 141-7.
9. Alexander BT, Bennett WA, Khalil RA, Granger JP. Preeclampsia: Linking placental ischemia with cardiovascular-renal dysfunction. News Physiol Sci 2001; 16: 282-6.
10. Lyall F. Priming and remodelling of human placental bed spiral arteries during pregnancy - a review. Placenta 2005; 26 (Suppl. A): S31-6.
11. Meekins JW, Pijnenborg R, Hanssens M, Mcfadyen IR, Van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669-74.
12. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1: 177-91.
13. Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000; 107: 196-208.
14. Goldman-Wohl D, Yagel S. Regulation of trophoblast invasion: From normal implantation to pre-eclampsia. Mol Cell Endocrinol 2002; 187: 233-8.
15. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003; 69: 1-7.
16. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008; 59: 61-78.
17. Fisher SJ. The placental problem: Linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004; 2: 53.
18. Zhou Y, Mcmaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405-23.
19. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-9.
20. Novaro V, Colman-Lerner A, Ortega FV, Jawerbaum A, Paz D, Lo Nostro F, Pustovrh C, Gimeno MF, Gonzalez E. Regulation of metalloproteinases by nitric oxide in human trophoblast cells in culture. Reprod Fertil Dev 2001; 13: 411-20.
21. Noris M, Perico N, Remuzzi G. Mechanisms of disease: Pre-eclampsia. Nat Clin Pract Nephrol 2005; 1: 98-114. quiz 120.
22. Redman CWG, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - a review. Placenta 2003; 24: S21-7.
23. Meziani F, Tesse A, David E, Martinez MC, Wangesteen R, Schneider F, Andriantsitohaina R. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol 2006; 169: 1473-83.
24. Smarason AK, Sargent IL, Starkey PM, Redman CWG. The effect of placental syncytiotrophoblast microvillous membranes from normal and preeclamptic women on the growth of endothelial-cells in-vitro. Br J Obstet Gynaecol 1993; 100: 943-9.
25. Cockell AP, Learmont JG, Smarason AK, Redman CWG, Sargent IL, Poston L. Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Br J Obstet Gynaecol 1997; 104: 235-40.
26. Tesse A, Meziani F, David E, Carusio N, Kremer H, Schneider F, Andriantsitohaina R. Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO. Am J Physiol Heart Circ Physiol 2007; 293: H520-5.
27. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical-evidence of endothelial-cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991; 4: 700-8.
28. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, Mclaughlin MK. Preeclampsia - an endothelial-cell disorder. Am J Obstet Gynecol 1989; 161: 1200-4.
29. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005; 45: 258-63.
30. Yoshida A, Nakao S, Kobayashi M, Kobayashi H. Flow-mediated vasodilation and plasma fibronectin levels in preeclampsia. Hypertension 2000; 36: 400-4.
31. Anim-Nyame N, Sooranna SR, Johnson MR, Gamble J, Steer PJ. A longitudinal study of resting peripheral blood flow in normal pregnancy and pregnancies complicated by chronic hypertension and pre-eclampsia. Cardiovasc Res 2001; 50: 603-9.
32. Anim-Nyame N, Sooranna SR, Johnson MR, Gamble J, Steer PJ. Resting peripheral blood flow in normal pregnancy and in pre-eclampsia. Clin Sci (Lond) 2000; 99: 505-10.
33. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285: 1607-12.
34. Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, Price K, Karumanchi SA, Valdes G. Endothelial dysfunction: A link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension 2007; 49: 90-5.
35. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, Mclaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: An indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004; 286: H1389-93.
36. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
37. Tsai W-C, Li Y-H, Huang Y-Y, Lin C-C, Chao T-H, Chen J-H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci 2005; 109: 39-43.
38. Than NG, Romero R, Hillermann R, Cozzi V, Nie G, Huppertz B. Prediction of preeclampsia - a workshop report. Placenta 2008; 29(Suppl. A): S83-5.
39. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. Mol Aspects Med 2007; 28: 227-44.
40. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckle HS. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006; 27: 13-7.
41. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993; 90: 10705-9.
42. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
43. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2: RE21.
44. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2007; 75: 1-8.
45. Mckeeman GC, Ardill JE, Caldwell CM, Hunter AJ, Mcclure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240-6.
46. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266-74.
47. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-5.
48. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58.
49. Livingston JC, Haddad B, Gorski LA, Neblett P, Ahokas RA, Ramsey R, Sibai BM. Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol 2001; 184: 1218-20.
50. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, The Cpep Study Group. Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. N Engl J Med 2006; 355: 992-1005.
51. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental Expression of Vascular Endothelial Growth Factor Receptor-1, (Flt-1) and Soluble Flt-1 (sFlt-1), by Peripheral Blood Mononuclear Cells (PBMCs) in Normotensive and Preeclamptic Pregnant Women. Placenta 2005; 26: 563-73.
52. Li Z, Zhang Y, Ying MAJ, Kapoun AM, Shao Q, Kerr I, Lam A, O'young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686-92.
53. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KimY, Goncalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541-7.
54. Bdolah Y, Palomaki GE, Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006; 194: 239-45.
55. Powers RW, Roberts JM, Cooper KM, Gallaher MJ, Frank MP, Harger GF, Ness RB. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193: 185-91.
56. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-9.
57. Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
58. Robb AO, Mills NL, Newby DE, Denison FC. Endothelial progenitor cells in pregnancy. Reproduction 2007; 133: 1-9.
59. Matsubara K, Abe E, Matsubara Y, Kameda K, Ito M. Circulating Endothelial Progenitor Cells During Normal Pregnancy and Pre-Eclampsia. Am J Reprod Immunol 2006; 56: 79-85.
60. Sugawara J, Mitsui-Saito M, Hoshiai T, Hayashi C, Kimura Y, Okamura K. Circulating Endothelial Progenitor Cells during Human Pregnancy. J Clin Endocrinol Metab 2005; 90: 1845-8.
61. Gussin HA, Bischoff FZ, Hoffman R, Elias S. Endothelial precursor cells in the peripheral blood of pregnant women. J Soc Gynecol Investig 2002; 9: 357-61.
62. Hill JM, Zalos G, Halcox JPJ, Schenke WH, Waclawiw MA, Quyyumi a A, Finkel T. Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk. N Engl J Med 2003; 348: 593-600.
63. Sugawara J, Mitsui-Saito M, Hayashi C, Hoshiai T, Senoo M, Chisaka H, Yaegashi N, Okamura K. Decrease and Senescence of Endothelial Progenitor Cells in Patients with Preeclampsia. J Clin Endocrinol Metab 2005; 90: 5329-32.
64. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, Isner JM, Asahara T, Losordo DW. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003; 108: 3115-21.
65. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101: 2382-7.
66. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Muller DN. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005; 45: 742-6.
67. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46: 1077-85.
68. Zhou CC, Zhang Y, Irani RA, Zhang H, M T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14: 855-62.
69. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol Regul Integr Comp Physiol 1997; 272: R441-63.
70. Kopp L, Paradiz G, Tucci JR. Urinary excretion of cyclic 3′,5′-adenosine monophosphate and cyclic 3′,5′-guanosine monophosphate during and after pregnancy. J Clin Endocrinol Metab 1977; 44: 590-4.
71. Meher S, Duley L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD006490.
72. Buhimschi I, Saade G, Chwalisz K, Garfield R. The nitric oxide pathway in pre-eclampsia: Pathophysiological implications. Hum Reprod Update 1998; 4: 25-42.
73. Eis AL, Brockman DE, Myatt L. Immunolocalization of the inducible nitric oxide synthase isoform in human fetal membranes. Am J Reprod Immunol 1997; 38: 289-94.
74. Myatt L, Brockman DE, Eis AL, Pollock JS. Immunohistochemical localization of nitric oxide synthase in the human placenta. Placenta 1993; 14: 487-95.
75. Eis AL, Brockman DE, Pollock JS, Myatt L. Immunohistochemical localization of endothelial nitric oxide synthase in human villous and extravillous trophoblast populations and expression during syncytiotrophoblast formation in vitro. Placenta 1995; 16: 113-26.
76. Myatt L, Eis AL, Brockman DE, Greer IA, Lyall F. Endothelial nitric oxide synthase in placental villous tissue from normal, pre-eclamptic and intrauterine growth restricted pregnancies. Hum Reprod 1997; 12: 167-72.
77. Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, Macconi D, Maucci R, Porrati F, Benigni A, Picciolo C, Remuzzi G. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 2004; 43: 614-22.
78. Reshef R, Schwartz D, Ingbir M, Shtabsky A, Chernichovski T, Isserlin BA, Chernin G, Levo Y, Schwartz IF. A profound decrease in maternal arginine uptake provokes endothelial nitration in the pregnant rat. Am J Physiol Heart Circ Physiol 2008; 294: H1156-63.
79. Holden DP, Fickling SA, Whitley GS, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998; 178: 551-6.
80. Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GS. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet 1993; 342: 242-3.
81. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361: 1511-7.
82. Buhimschi I, Yallampalli C, Chwalisz K, Garfield RE. Pre-eclampsia-like conditions produced by nitric oxide inhibition: Effects of L-arginine, D-arginine and steroid hormones. Hum Reprod 1995; 10: 2723-30.
83. Miller MJ, Voelker CA, Olister S, Thompson JH, Zhang XJ, Rivera D, Eloby-Childress S, Liu X, Clark DA, Pierce MR. Fetal growth retardation in rats may result from apoptosis: Role of peroxynitrite. Free Radic Biol Med 1996; 21: 619-29.
84. Diejomaoh FM, Omu AE, Al-Busiri N, Taher S, Al-Othman S, Fatinikun T, Fernandes S. Nitric oxide production is not altered in preeclampsia. Arch Gynecol Obstet 2004; 269: 237-43.
85. Ranta V, Viinikka L, Halmesmaki E, Ylikorkala O. Nitric oxide production with preeclampsia. Obstet Gynecol 1999; 93: 442-5.
86. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1994; 171: 944-8.
87. Lyall F, Young A, Greer IA. Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia. Am J Obstet Gynecol 1995; 173: 714-8.
88. Di Iorio R, Marinoni E, Emiliani S, Villaccio B, Cosmi EV. Nitric oxide in preeclampsia: Lack of evidence for decreased production. Eur J Obstet Gynecol Reprod Biol 1998; 76: 65-70.
89. Burton GJ, Hempstock J, Jauniaux E. Oxygen, early embryonic metabolism and free radical-mediated embryopathies. Reprod Biomed Online 2003; 6: 84-96.
90. Wang YP, Walsh SW, Kay HH. Placental Lipid Peroxides and Thromboxane Are Increased and Prostacyclin Is Decreased in Women with Preeclampsia. Am J Obstet Gynecol 1992; 167: 946-9.
91. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999; 222: 222-35.
92. Wang Y, Walsh SW. Placental mitochondria as a source of oxidative stress in pre-eclampsia. Placenta 1998; 19: 581-6.
93. Schumacker PT. Current paradigms in cellular oxygen sensing. Adv Exp Med Biol 2003; 543: 57-71.
94. Cui X-L, Brockman D, Campos B, Myatt L. Expression of NADPH Oxidase Isoform 1 (Nox1) in Human Placenta: Involvement in Preeclampsia. Placenta 2006; 27: 422-31.
95. Barber A, Robson SC, Myatt L, Bulmer JN, Lyall F. Heme oxygenase expression in human placenta and placental bed: Reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction. FASEB J 2001; 15: 1158-68.
96. Many A, Hubel CA, Fisher SJ, Roberts JM, Zhou Y. Invasive Cytotrophoblasts Manifest Evidence of Oxidative Stress in Preeclampsia. Am J Pathol 2000; 156: 321-31.
97. Raijmakers MTM, Dechend R, Poston L. Oxidative Stress and Preeclampsia: Rationale for Antioxidant Clinical Trials. Hypertension 2004; 44: 374-80.
98. Wang Y, Walsh SW. Antioxidant activities and mRNA expression of superoxide dismutase, catalase, and glutathione peroxidase in normal and preeclamptic placentas. J Soc Gynecol Investig 1996; 3: 179-84.
99. Llurba E, Gratacos E, Martin-Gallan P, Cabero L, Dominguez C. A comprehensive study of oxidative stress and antioxidant status in preeclampsia and normal pregnancy. Free Radic Biol Med 2004; 37: 557-70.
100. Sharma JB, Sharma A, Bahadur A, Vimala N, Satyam A, Mittal S. Oxidative stress markers and antioxidant levels in normal pregnancy and pre-eclampsia. Int J Gynaecol Obstet 2006; 94: 23-7.
101. Mikhail MS, Anyaegbunam A, Garfinkel D, Palan PR, Basu J, Romney SL. Preeclampsia and antioxidant nutrients: Decreased plasma levels of reduced ascorbic acid, alpha-tocopherol, and beta-carotene in women with preeclampsia. Am J Obstet Gynecol 1994; 171: 150-7.
102. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367: 1145-54.
103. Rumbold A, Duley L, Crowther CA, Haslam RR. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 2008; 1: CD004227.
104. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996; 9: 836-44.
105. Peluffo G, Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res 2007; 75: 291-302.
106. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007; 6: 662-80.
107. Webster RP, Brockman D, Myatt L. Nitration of p38 MAPK in the placenta: association of nitration with reduced catalytic activity of p38 MAPK in pre-eclampsia. Mol Hum Reprod 2006; 11: 677-85.
108. Webster RP, Macha S, Brockman D, Myatt L. Peroxynitrite treatment in vitro disables catalytic activity of recombinant p38 MAPK. Proteomics 2006; 6: 4838-44.
109. Roberts VH, Webster RP, Brockman DE, Pitzer BA, Myatt L. Post-translational modifications of the P2X(4) purinergic receptor subtype in the human placenta are altered in preeclampsia. Placenta 2007; 28: 270-7.
110. Webster RP, Roberts VHR, Myatt L. Protein nitration in placenta - functional significance. Placenta 2008; 12: 985-94.
111. Lyall F, Gibson JL, Greer IA, Brockman DE, Eis AL, Myatt L. Increased nitrotyrosine in the diabetic placenta: Evidence for oxidative stress. Diabetes Care 1998; 21: 1753-8.
112. Myatt L, Rosenfield RB, Eis AL, Brockman DE, Greer I, Lyall F. Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension 1996; 28: 488-93.
113. Stanek J, Eis ALW, Myatt L. Nitrotyrosine immunostaining correlates with increased extracellular matrix: Evidence of postplacental hypoxia. Placenta 2001; 22: S56-62.
114. Roggensack AM, Zhang Y, Davidge ST. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 1999; 33: 83-9.
115. Kossenjans W, Eis A, Sahay R, Brockman D, Myatt L. Role of peroxynitrite in altered fetal-placental vascular reactivity in diabetes or preeclampsia. Am J Physiol Heart Circ Physiol 2000; 278: H1311-9.
116. El-Remessy AB, Al-Shabrawey M, Platt DH, Bartoli M, Behzadian MA, Ghaly N, Tsai N, Motamed K, Caldwell RB. Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells. FASEB J 2007; 21: 2528-39.
117. Hassanain HH, Gregg D, Marcelo ML, Zweier JL, Souza HP, Selvakumar B, Ma Q, Moustafa-Bayoumi M, Binkley PF, Flavahan NA, Morris M, Dong C, Goldschmidt-Clermont PJ. Hypertension caused by transgenic overexpression of Rac1. Antioxid Redox Signal 2007; 9: 91-100.
118. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. Jama 2003; 289: 1675-80.
119. Lanone S, Manivet P, Callebert J, Launay JM, Payen D, Aubier M, Boczkowski J, Mebazaa A. Inducible nitric oxide synthase (NOS2) expressed in septic patients is nitrated on selected tyrosine residues: implications for enzymic activity. Biochem J 2002; 366: 399-404.
120. Zou MH. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat 2007; 82: 119-27.
121. Boulos C, Jiang H, Balazy M. Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues. J Pharmacol Exp Ther 2000; 293: 222-9.
122. Myatt L. Role of placenta in preeclampsia. Endocr 2002; 19: 103-11.
123. Redman CWG, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499-506.
124. Ray J. Metabolic syndrome and higher risk of maternal placental syndromes and cardiovascular disease. Drug Dev Res 2006; 67: 607-11.
125. Ness RB, Hubel CA. Risk for coronary artery disease and morbid preeclampsia: A commentary. Ann Epidemiol 2005; 15: 726-33.
126. Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue XN, Deutsch L, Harlap S. Long-term mortality after preeclampsia. Epidemiology 2005; 16: 206-15.
127. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: Population based cohort study. Br Med J 2001; 323: 1213-6.
128. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74: 772-6.
129. Wikstrom A-K, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG: An Internat J Obstet Gynaecol 2005; 112: 1486-91.
130. Barden A, Singh R, Walters BN, Ritchie J, Roberman B, Beilin LJ. Factors predisposing to pre-eclampsia in women with gestational diabetes. J Hypertens 2004; 22: 2371-8.
131. Barden AE, Beilin LJ, Ritchie L, Walters BN, Michael C. Does a predisposition to the metabolic syndrome sensitize women to develop pre-eclampsia? J Hypertens 1999; 17: 1307-15.
132. Barden A, Ritchie J, Walters B, Michael C, Rivera J, Mori T, Croft K, Beilin L. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertension 2001; 38: 803-8.
133. Barden A. Pre-eclampsia: Contribution of maternal constitutional factors and the consequences for cardiovascular health. Clin Exp Pharmacol Physiol 2006; 33: 826-30.
134. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: A retrospective cohort study of 290 births. Lancet 2001; 357: 2002-6.
135. Zetterstrom K, Lindeberg S, Haglund B, Magnuson A, Hanson U. Being born small for gestational age increases the risk of severe pre-eclampsia. BJOG: An Internat J Obstet Gynaecol 2007; 114: 319-24.
136. Walsh SW. Obesity: A risk factor for preeclampsia. Trends Endocrinol Metab 2007; 18: 365-70.
137. Bodnar LM, Ness RB, Markovic N, Roberts JM. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol 2005; 15: 475-82.
138. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: A population-based study. Lancet 2006; 368: 1164-70.
139. Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte biology. Adipocyte stress: The endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48: 1905-14.
140. Desoye G, Hauguel-De Mouzon S. The human placenta in gestational diabetes mellitus: The insulin and cytokine network. Diabetes Care 2007; 30: S120-6.
141. Radaelli T, Varastehpour A, Catalano P, Hauguel-De Mouzon S. Gestational diabetes induces placental genes for chronic stress and inflammatory pathways. Diabetes 2003; 52: 2951-8.
142. Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and type 2 diabetes. Novartis Found Symp 2007; 88: 162-3.
143. Webster RP, Pitzer BA, Roberts VHJ, Brockman D, Myatt L. Differences in the proteome profile in placenta from normal term and preeclamptic preterm pregnancies. Proteomics Clin Appl 2007; 1: 446-56.
144. Zhang K, Kaufman RJ. The unfolded protein response: A stress signaling pathway critical for health and disease. Neurology 2006; 66: S102-9.
145. Yung H-W, Korolchuk S, Tolkovsky AM, Charnock-Jones DS, Burton GJ. Endoplasmic reticulum stress exacerbates ischemia-reperfusion-induced apoptosis through attenuation of Akt protein synthesis in human choriocarcinoma cells. FASEB J 2007; 21: 872-84.